The Filing Desk

Beam Therapeutics vs Karyopharm Therapeutics

Beam Therapeutics BEAM · Karyopharm Therapeutics KPTI · Biotechnology

Karyopharm Therapeutics reported revenue of $146 million in fiscal 2025, about the same as Beam Therapeutics' $140 million in fiscal 2025. Beam Therapeutics' revenue grew 120.0% in its latest year, and Karyopharm Therapeutics' grew 0.6%. Beam Therapeutics had an operating margin of -274.6%, against -62.1% at Karyopharm Therapeutics. Free cash flow was −$360 million at Beam Therapeutics and −$75 million at Karyopharm Therapeutics.

Side by side

Beam TherapeuticsKaryopharm Therapeutics
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$140M$146M
Revenue growth120.0%0.6%
Revenue growth a year, last 5 years—6.2%
Gross margin——
Operating margin−274.6%−62.1%
Net margin−57.2%−134.2%
Free cash flow−$360M−$75M
Free cash flow margin−257.6%−51.6%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count20.2%129,231.8%
Last close$20.94$0.02
P/E at the last close——
Insider trades, last 12 monthssold $18.5 million—
Piotroski F-score—2 of 8
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Beam TherapeuticsKaryopharm Therapeutics
Operating margin
Percent of revenue
Beam TherapeuticsKaryopharm Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Beam TherapeuticsKaryopharm Therapeutics

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Beam Therapeutics and Karyopharm Therapeutics pages.